title: Tumor-specific cytolysis caused by an E1B55K-attenuated adenovirus in nasopharyngeal carcinoma is augmented by cisplatin.
abstract: An E1B55K-attenuated adenovirus, dl1520, has been shown to replicate selectively in and lyse tumor cells. In this study, the antitumor activities of dl1520, alone or in combination with the chemotherapeutic agent cisplatin, were investigated in nasopharyngeal carcinoma (NPC) cells. The results demonstrated that dl1520 replicated in and destroyed NPC cells, and induced apoptosis in vitro. In a nude mouse xenograft model, dl1520 significantly inhibited the growth of NPC cell xenografts, and the viral replication was associated with tumor regression. Importantly, the antitumor activity of dl1520 was augmented by the addition of cisplatin both in vitro and in vivo, showing that dl1520 and cisplatin have a synergistic anti-NPC effect. These data suggest that dl1520 exerts an efficient anti-NPC activity through oncolysis and the induction of apoptosis, which is enhanced synergistically by cisplatin. These findings indicate that oncolytic viral therapeutics using the E1B55K-attenuated adenovirus dl1520 could be promising in the comprehensive treatment of NPC, especially in combination with platinum-based chemotherapy.
authors.affiliation: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China.
authors.forename: Ran-Yi
authors.initials: RY
authors.lastname: Liu
authors.forename: Ji-Lin
authors.initials: JL
authors.lastname: Peng
authors.forename: Yong-Qiang
authors.initials: YQ
authors.lastname: Li
authors.forename: Bi-Jun
authors.initials: BJ
authors.lastname: Huang
authors.forename: Huan-Xin
authors.initials: HX
authors.lastname: Lin
authors.forename: Ling
authors.initials: L
authors.lastname: Zhou
authors.forename: Hui-Ling
authors.initials: HL
authors.lastname: Luo
authors.forename: Wenlin
authors.initials: W
authors.lastname: Huang
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis; D015153:Blotting, Western; D002277:Carcinoma; D049109:Cell Proliferation; D002945:Cisplatin / Q000008:administration & dosage; D004357:Drug Synergism; D006801:Humans; D007124:Immunoenzyme Techniques; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000473:pathology* / Q000628:therapy*; D014407:Tumor Cells, Cultured; D014613:Vaccines, Attenuated / Q000494:pharmacology*; D014765:Viral Vaccines / Q000008:administration & dosage; D023041:Xenograft Model Antitumor Assays
chemical_list: D014613:Vaccines, Attenuated; D014765:Viral Vaccines; C464532:dl1520; D002945:Cisplatin
keywords: E1B55K-attenuated adenovirus; chemotherapy; cisplatin; dl1520; nasopharyngeal carcinoma